Slides from conference were the SOS. Nothing new or revealing. Corporate still calling for revenues of $152 - $157MM, EPS $0.62 - $0.68 EPS GAAP with cash & investments of $90MM ($89MM as of 9/30/12). Zadaxin YOY growth despite heavy competition from local generics.
I didn't hear the conference. Does anyone have anything to add??